SCHEMBL25824021

SCHEMBL25824021

Clc1nc2cc(I)ccc2n2ccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 2/20 0.40
HTR3B O95264 2/20 0.40
HTR3A P46098 2/20 0.40
HTR3D Q70Z44 2/20 0.40
HTR3C Q8WXA8 2/20 0.40
IKBKB O14920 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIA1 P42261 1/20 0.35
GRIA2 P42262 1/20 0.35
GRIA3 P42263 1/20 0.35
GRIA4 P48058 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
MAPK8 P45983 8/20 0.35
HRH4 Q9H3N8 3/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30973203 0.88 IKBKB (0.45) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL25824093 0.88 IKBKB (0.45) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3496046 0.82 HTR3E (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL8279650 0.79 HTR3E (0.38) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL124061 0.78 KDM4E (0.51) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL31377522 0.78 MAPK8 (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3498276 0.78 KDM4E (0.42) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18584266 0.78 RAD51 (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL120846 0.78 MAPK8 (0.54) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL30578099 0.78 MAPK8 (0.54) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 HTR3E 2311/4885HTR3B 1466/4885HTR3A 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.